GENERAL
Glenmark Scales Up US Injectables Presence With Generic Sugammadex
Glenmark Pharmaceuticals Inc., USA, has launched Sugammadex Injection in the United States, expanding its injectables portfolio with a generic version of Merck Sharp & Dohme LLC’s blockbuster anaesthesia reversal drug BRIDION. The company said the product is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. Glenmark’s Sugammadex Injection […]
CW Bureau
·
Jul 29, 2026
GENERAL
Aurobindo Pharma USA Gets USFTC Nod For $250-Mn Lannett acquisition
Aurobindo Pharma USA, Inc, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received approval from the US Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end […]
CW Bureau
·
Jun 22, 2026
GENERAL
Indian Pharma Firms To Gain Up To $5 Bn From Global Patent Cliff: CareEdge
Indian pharmaceutical companies are poised to benefit from a major global patent expiry cycle, with drugs generating nearly $142 billion in sales in CY25 set to lose exclusivity between 2026 and 2030, according to a report by CareEdge Ratings. The report estimates that the upcoming patent cliff could create a market opportunity of over $30-40 […]
CW Bureau
·
Jun 19, 2026
GENERAL
Aurobindo Pharma Gets USFDA Nod For Dapagliflozin-Metformin Combo
Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride extended-release tablets in multiple strengths such as 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg. The approved formulation is bioequivalent and therapeutically equivalent to the reference listed […]
CW Bureau
·
Apr 7, 2026
